Aligos Therapeutics, Inc.: Alyeska Investment Group, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Alyeska Investment Group, L.P. amended its Schedule 13G stake filing for Aligos Therapeutics, Inc., according to SEC accession 0001172661-26-005360. The filing updates the investment firm's previously reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed when a passive investor's ownership crosses the 5% threshold or when previously reported holdings change materially. The exact revised share count and ownership percentage were not disclosed in the filing summary. Investors will watch for further 13G or 13D filings to gauge whether Alyeska's position is growing or being trimmed.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aligos Therapeutics, Inc., Alyeska Investment Group, L.P.